| 1. |
- Kirsebom, O. S., et al.
(författare)
-
Measurement of the 2+→0+ ground-state transition in the β decay of F 20
- 2019
-
Ingår i: Physical Review C. - 2469-9985. ; 100:6
-
Tidskriftsartikel (refereegranskat)abstract
- We report the first detection of the second-forbidden, nonunique, 2+→0+, ground-state transition in the β decay of F20. A low-energy, mass-separated F+20 beam produced at the IGISOL facility in Jyväskylä, Finland, was implanted in a thin carbon foil and the β spectrum measured using a magnetic transporter and a plastic-scintillator detector. The β-decay branching ratio inferred from the measurement is bβ=[0.41±0.08(stat)±0.07(sys)]×10-5 corresponding to logft=10.89(11), making this one of the strongest second-forbidden, nonunique β transitions ever measured. The experimental result is supported by shell-model calculations and has significant implications for the final evolution of stars that develop degenerate oxygen-neon cores. Using the new experimental data, we argue that the astrophysical electron-capture rate on Ne20 is now known to within better than 25% at the relevant temperatures and densities.
|
|
| 2. |
- Sels, S., et al.
(författare)
-
Doppler and sympathetic cooling for the investigation of short-lived radioactive ions
- 2022
-
Ingår i: Physical Review Research. - 2643-1564. ; 4:3
-
Tidskriftsartikel (refereegranskat)abstract
- At radioactive ion beam (RIB) facilities, ions of short-lived radionuclides are cooled and bunched in buffer-gas-filled Paul traps to improve the ion-beam quality for subsequent experiments. To deliver even colder ions, beneficial to RIB experiments' sensitivity or accuracy, we employ Doppler and sympathetic cooling in a Paul trap cooler-buncher. The improved emittance of Mg+, K+, and O2+ ion beams is demonstrated by a reduced time-of-flight spread of the extracted ion bunches with respect to room-temperature buffer-gas cooling. Cooling externally-produced hot ions with energies of at least 7 eV down to a few Kelvin is achieved in a timescale of O(100 ms) by combining a low-pressure helium background gas with laser cooling. This is sufficiently short to cool short-lived radioactive ions. As an example of this technique's use for RIB research, the mass-resolving power in a multireflection time-of-flight mass spectrometer is shown to increase by up to a factor of 4.6 with respect to buffer-gas cooling. Simulations show good agreement with the experimental results and guide further improvements and applications. These results open a path to a significant emittance improvement and, thus, unprecedented ion-beam qualities at RIB facilities, achievable with standard equipment readily available. The same method provides opportunities for future high-precision experiments with radioactive cold trapped ions.
|
|
| 3. |
- Lorenz, Ch, et al.
(författare)
-
β Decay of 127Cd and Excited States in 127In
- 2019
-
Ingår i: Physical Review C. - 2469-9985. ; 99:4
-
Tidskriftsartikel (refereegranskat)abstract
- A dedicated spectroscopic study of the β decay of 127Cd was conducted at the IGISOL facility at the University of Jyväskylä. Following high-resolution mass separation in a Penning trap, β-γ-γ coincidences were used to considerably extend the decay scheme of 127In. The β-decaying 3/2+ and 11/2- states in 127Cd have been identified with the 127Cd ground state and the 283-keV isomer. Their respective half-lives have been measured to 0.45(+12-8)s and 0.36(4) s. The experimentally observed β feeding to excited states of 127In and the decay scheme of 127In are discussed in conjunction with large-scale shell-model calculations.
|
|
| 4. |
|
|
| 5. |
- Vilen, ST, et al.
(författare)
-
Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: Possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma
- 2008
-
Ingår i: Experimental Cell Research. - : Elsevier BV. - 1090-2422 .- 0014-4827. ; 314:4, s. 914-926
-
Tidskriftsartikel (refereegranskat)abstract
- Tumor-associated trypsin-2 and matrix metalloprotease-9 (MMP-9) are associated with cancer, particularly with invasive squamous cell carcinomas. They require activation for catalytical competence via proteolytic cascades. One cascade is formed by enterokinase, trypsin-2 and MMP-9; enterokinase activates trypsinogen-2 to trypsin-2, which is an efficient proMMP-9 activator. We describe here that oral squamous cell carcinomas express all members of this cascade: MMP-9, trypsin-2 and enterokinase. The expression of enterokinase in a carcinoma cell line not derived from the duodenum was shown here for the first time. Enterokinase directly cleaved proMMP-9 at the Lys(65)-Ser(66) site, but failed to activate it in vitro. We demonstrated by confocal microscopy that MMP-9 and trypsin-2 co-localized in intracellular vesicles of the carcinoma cells. This co-localization of trypsin-2 and MMP-9 resulted in intracellular proMMP-9 processing that represented fully or partially activated MMP-9. However, although both proteases were present also in various bone tumor tissues, MMP-9 and trypsin-2 never co-localized at the cellular level in these tissues. This suggests that the intracellular vesicular co-localization, storage and possible activation of these proteases may be a unique feature for aggressive epithelial tumors, such as squamous cell carcinomas, but not for tumors of mesenchymal origin.
|
|
| 6. |
|
|
| 7. |
- Maastrup, Ragnhild, et al.
(författare)
-
Compliance with the Baby-friendly Hospital Initiative for Neonatal Wards (Neo-BFHI) : A cross-sectional study in 36 countries
- 2019
-
Ingår i: Maternal and Child Nutrition. - : Blackwell Science Ltd.. - 1740-8695 .- 1740-8709. ; 15:2
-
Tidskriftsartikel (refereegranskat)abstract
- In 2012, the Baby-friendly Hospital Initiative for Neonatal Wards (Neo-BFHI) began providing recommendations to improve breastfeeding support for preterm and ill infants. This cross-sectional survey aimed to measure compliance on a global level with the Neo-BFHI’s expanded Ten steps to Successful Breastfeeding and three Guiding Principles in neonatal wards. In 2017 the Neo-BFHI Self-Assessment questionnaire was used in 15 languages to collect data from neonatal wards of all levels of care. Answers were summarized into compliance scores ranging from 0 to 100 at the ward, country and international levels. A total of 917 neonatal wards from 36 low, middle and high-income countries from all continents participated. The median international overall score was 77, and median country overall scores ranged from 52 to 91. Guiding Principle 1 (respect for mothers), Step 5 (breastfeeding initiation and support), and Step 6 (human milk use) had the highest scores, 100, 88, and 88, respectively. Steps 3 (antenatal information) and 7 (rooming-in) had the lowest scores, 63 and 67, respectively. High-income countries had significantly higher scores for Guiding principle 2 (family-centered care), Step 4 (skin-to-skin contact) and Step 5. Neonatal wards in hospitals ever-designated Baby-friendly had significantly higher scores than those never designated. Sixty percent of managers stated they would like to obtain Neo-BFHI designation. Currently, Neo-BFHI recommendations are partly implemented in many countries. The high number of participating wards indicates international readiness to expand Baby-friendly standards to neonatal settings. Hospitals and governments should increase their efforts to better support breastfeeding in neonatal wards.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Weghuber, D., et al.
(författare)
-
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
- 2020
-
Ingår i: Pediatric Obesity. - 2047-6302 .- 2047-6310. ; 15:7
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity.OBJECTIVE: To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity.METHODS: Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention.RESULTS: Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm3 ; -989, -114), 2-hour-glucose during OGTT (-15.3 mg/dL; -27.5, -3.1), total cholesterol (11.6 mg/dL; -21.7, -1.5), and BMI (-0.83 kg/m2 ; -1.68, 0.01) without significant change in liver fat content (-1.36; -3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide-treated patients.CONCLUSIONS: Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.
|
|
